|
|
 |
|
Viewing report
|
|
|
|
Pipeline Insight: Neuropathic Pain - Emerging Drugs Fail to Capitalize in Lucrative Market
Datamonitor, Sep 2007, Pages: 217
The neuropathic pain market is forecast to double from 2006 to reach over $7 billion by 2016.
At this time, the current late-stage neuropathic pain pipeline is forecast to take only 18% of the total market share, highlighting an opportunity for better pipeline drugs that demonstrate improved pain management.
The most promising and closest pipeline drug to market is UCBs Vimpat (lacosamide).
Scope
Analysis of patient potential, unmet needs and clinical trial design in neuropathic pain
Overview of drugs in late- and early-stage clinical development; with analysis of key companies involved in the market
Detailed profiles of key compounds in development for use in neuropathic pain, with indication-specific drug sales forecasts to 2016
Discussion of Pfizer, Eli Lilly and UCBs market strategies and insight from key opinion leaders
Highlights
UCBs increasing CNS portfolio is further bolstered by the imminent arrival of Vimpat on the market. CNS is a key area of investigation for UCB, constituting 39% of their sales in 2006. UCB has further expanded its reach by trialling this anticonvulsant not just for epilepsy but also for neuropathic pain, fibromyalgia, migraine and osteoarthritis. NeurogesXs Transacin (capsaicin) treatment is set to cause a stir in the topical market, currently dominated by Endos Lidoderm (lidocaine 5% patch). The advantageous 3 monthly dosing regimen coupled with a strong efficacy and safety profile, will see Transacin draw favorable returns in its niche market. Pfizer will continue to be a major contender in neuropathic pain, with the current market leader Lyrica predicted to be an even greater commercial success than its predecessor Neurontin (gabapentin). Pfizers branded drugs are forecast to capture a substantial 41% of the neuropathic pain market share in 2016.
Reasons to Purchase
Understand unmet needs in the neuropathic pain market based on key opinion leader insight
Benchmark key late-stage neuropathic pain compounds against current market leaders
Assess the global (US, Japan, five major EU) sales forecasts of key late-stage pipeline drugs; and examine their clinical and commercial potential
Customers who bought this item also bought
Peripheral Neuropathy and Neuropathic Pain
Pipeline Insight: Neuropathic Pain - Pipeline Drugs Fail To Nail Neuropathic Pain
US Neuropathic Pain 2008 - 4th Edition: Market Potential Through 2018
Neuropathic Pain Insight - Life Beyond Gabapentin
Commercial Insight: Neuropathic Pain - A Plethora of Patient Segmentation and Product Differentiation Opportunities
Neuropathic Pain: Treatments and Prescribing Practices - A Global Survey 2009
US Cancer Pain Report
Pain Therapeutics - Drugs, Markets and Companies
Stakeholder Insight: Diabetic Neuropathic Pain - Market Success is Not Limited to Pregabalin
Stakeholder Insight: Neuropathic Pain - Comparative Overview of Treatment Preferences Across the Seven Major Markets
Stakeholder Insight: HIV Related Neuropathic Pain - Useful Niche for Peripheral Companies
Stakeholder Insight: Neuropathic Low Back Pain - Off-label Revenue Despite Diagnostic Challenge
|
|
|
|
